Patrick Wareing
LightNews LightNews
patrickwareing.bsky.social
Patrick Wareing
@patrickwareing.bsky.social
84 followers 490 following 280 posts
Weekly news to your inbox every Monday morning 👉https://patrickwareing.kit.com/a70ed18837
Posts Replies Media Videos
Pinned
patrickwareing.bsky.social
Patrick Wareing @patrickwareing.bsky.social · Jul 24
Too much news? Not enough time?

Stay up to date with the latest B2B life science news

patrickwareing.kit.com/email-signup
Life Science News to Your Inbox
Get a weekly summary of the past week's life science, pharma and biotech news
patrickwareing.kit.com
patrickwareing.bsky.social
Moderna Announces New Manufacturing Partnership in China

patrickwareing.com/news/moderna...
Moderna Announces New Manufacturing Partnership in China - Patrick Wareing
Moderna, the U.S.-based biotechnology company, has announced a significant new manufacturing partnership in China, formalizing its first major investment in
patrickwareing.com
November 28, 2025 at 4:45 PM
patrickwareing.bsky.social
eXmoor Pharma and Royal Free London Announce Strategic Collaboration on Gene Therapy Manufacturing

patrickwareing.com/news/exmoor-...
eXmoor Pharma and Royal Free London Announce Strategic Collaboration on Gene Therapy Manufacturing - Patrick Wareing
eXmoor Pharma, an integrated cell and gene therapy contract development and manufacturing organisation (CDMO), and Royal Free London NHS Foundation Trust have
patrickwareing.com
November 28, 2025 at 2:15 PM
patrickwareing.bsky.social
Medicare Unveils Price Reductions for 15 Drugs, Including Novo Nordisk’s Semaglutide

patrickwareing.com/news/medicar...
Medicare Unveils Price Reductions for 15 Drugs, Including Novo Nordisk's Semaglutide - Patrick Wareing
Medicare has announced substantial price reductions for 15 widely used prescription drugs, marking the second major round of negotiations under the Inflation
patrickwareing.com
November 28, 2025 at 11:45 AM
patrickwareing.bsky.social
Otsuka Secures FDA Approval for Voyxact in Kidney Disease Space

patrickwareing.com/news/otsuka-...
Otsuka Secures FDA Approval for Voyxact in Kidney Disease Space - Patrick Wareing
Otsuka Pharmaceutical achieved a significant regulatory milestone on November 25, 2025, when the U.S. Food and Drug Administration granted accelerated
patrickwareing.com
November 27, 2025 at 4:45 PM
patrickwareing.bsky.social
Sanofi Faces Tax Fraud Probe Involving Multiple Companies

patrickwareing.com/news/sanofi-...
Sanofi Faces Tax Fraud Probe Involving Multiple Companies - Patrick Wareing
French pharmaceutical giant Sanofi faced heightened regulatory scrutiny on November 25, 2025, when approximately 30 judicial tax officers from the National
patrickwareing.com
November 27, 2025 at 2:15 PM
patrickwareing.bsky.social
Valneva Shuts Down R&D and Operations Facility, Cuts 30 Jobs

patrickwareing.com/news/valneva...
Valneva Shuts Down R&D and Operations Facility, Cuts 30 Jobs - Patrick Wareing
Valneva, a specialty vaccine company, announced on November 26, 2025, a significant organizational restructuring involving the closure of its Nantes facility
patrickwareing.com
November 27, 2025 at 11:45 AM
patrickwareing.bsky.social
FDA Approves Novartis’ Itvisma Gene Therapy for Rare Muscle Disorder, Expanding Treatment Options for Spinal Muscular Atrophy

patrickwareing.com/news/fda-app...
FDA Approves Novartis’ Itvisma Gene Therapy for Rare Muscle Disorder, Expanding Treatment Options for Spinal Muscular Atrophy - Patrick Wareing
Novartis announced the FDA approval of Itvisma, a novel gene replacement therapy designed for individuals living with spinal muscular atrophy (SMA) aged two
patrickwareing.com
November 26, 2025 at 4:15 PM
patrickwareing.bsky.social
Moderna Secures $1.5 Billion Funding to Support Growth, Targets Break-Even by 2028 While Advancing Oncology and Rare Disease Programs

patrickwareing.com/news/moderna...
Moderna Secures $1.5 Billion Funding to Support Growth, Targets Break-Even by 2028 While Advancing Oncology and Rare Disease Programs - Patrick Wareing
Moderna, Inc. announced it has secured a five-year, $1.5 billion debt facility with Ares Management Credit Funds to fund its growth and provide financial
patrickwareing.com
November 26, 2025 at 2:45 PM
patrickwareing.bsky.social
Aspen Neuroscience Secures $115 Million Series C Funding to Advance Parkinson’s Stem Cell Therapy

patrickwareing.com/news/aspen-n...
Aspen Neuroscience Secures $115 Million Series C Funding to Advance Parkinson’s Stem Cell Therapy - Patrick Wareing
Aspen Neuroscience, a clinical-stage biotech pioneer in personalized regenerative therapies, announced the successful close of a $115 million Series C funding
patrickwareing.com
November 26, 2025 at 12:01 PM
patrickwareing.bsky.social
Alkermes Raises Offer in Intense Bidding War for Avadel Pharmaceuticals

patrickwareing.com/news/alkerme...
Alkermes Raises Offer in Intense Bidding War for Avadel Pharmaceuticals - Patrick Wareing
Alkermes has significantly escalated its pursuit of Avadel Pharmaceuticals , a biotech company specializing in treatments for sleep disorders, by raising its
patrickwareing.com
November 25, 2025 at 4:45 PM
patrickwareing.bsky.social
Novo Nordisk’s Semaglutide Fails to Meet Primary Endpoints in Alzheimer’s Phase 3 Trials

patrickwareing.com/news/novo-no...
Novo Nordisk’s Semaglutide Fails to Meet Primary Endpoints in Alzheimer’s Phase 3 Trials - Patrick Wareing
Novo Nordisk , the Danish pharmaceutical company known for blockbuster diabetes and obesity treatments Ozempic and Wegovy, disclosed top-line results from its
patrickwareing.com
November 25, 2025 at 2:15 PM
patrickwareing.bsky.social
Regeneron Pharmaceuticals Receives Two New FDA Approvals for Higher-Dose Eylea

patrickwareing.com/news/regener...
Regeneron Pharmaceuticals Receives Two New FDA Approvals for Higher-Dose Eylea - Patrick Wareing
Regeneron Pharmaceuticals secured two significant FDA approvals for its high-dose Eylea (8 mg aflibercept), a key drug for serious eye diseases. The first
patrickwareing.com
November 25, 2025 at 11:45 AM
patrickwareing.bsky.social
GHO Capital Partners Completes Acquisition of Scientist.com

patrickwareing.com/news/gho-cap...
November 24, 2025 at 4:45 PM
patrickwareing.bsky.social
Moderna Completes U.S. mRNA Manufacturing Network with $140 Million Investment in Norwood Facility

patrickwareing.com/news/moderna...
Moderna Completes U.S. mRNA Manufacturing Network with $140 Million Investment in Norwood Facility - Patrick Wareing
Moderna, the Massachusetts-based biotech pioneer known for its COVID-19 mRNA vaccines, is significantly bolstering its U.S. manufacturing footprint with a
patrickwareing.com
November 24, 2025 at 2:00 PM
patrickwareing.bsky.social
Roche Secures $200M Licensing Pact for Freenome’s Blood-Based Cancer Screening

patrickwareing.com/news/roche-s...
Roche Secures $200M Licensing Pact for Freenome’s Blood-Based Cancer Screening - Patrick Wareing
Roche has deepened its bet on blood-based cancer screening by signing a broad licensing and collaboration agreement with Freenome, a California-based
patrickwareing.com
November 24, 2025 at 11:12 AM
patrickwareing.bsky.social
Alkermes and Lundbeck Engage in Bidding War Over Sleep Biotech Avadel Pharmaceuticals, Valued Around $2.4 Billion

patrickwareing.com/news/alkerme...
Alkermes and Lundbeck Engage in Bidding War Over Sleep Biotech Avadel Pharmaceuticals, Valued Around $2.4 Billion - Patrick Wareing
Avadel Pharmaceuticals finds itself in a heated acquisition contest as two prominent players vie for control of the sleep-focused biotech. Alkermes initially
patrickwareing.com
November 21, 2025 at 4:45 PM
patrickwareing.bsky.social
Medicxi Closes €500 Million Fund V to Advance Asset-Centric Biotech Innovation Across Europe and the U.S.

patrickwareing.com/news/medicxi...
Medicxi Closes €500 Million Fund V to Advance Asset-Centric Biotech Innovation Across Europe and the U.S. - Patrick Wareing
Medicxi has closed its largest investment vehicle to date, €500 million Fund V, marking a significant milestone in the firm’s commitment to fostering
patrickwareing.com
November 21, 2025 at 2:45 PM
patrickwareing.bsky.social
Abbott Laboratories Moves to Acquire Exact Sciences in $23 Billion Deal to Expand Cancer Diagnostics

patrickwareing.com/news/abbott-...
Abbott Laboratories Moves to Acquire Exact Sciences in $23 Billion Deal to Expand Cancer Diagnostics - Patrick Wareing
Abbott Laboratories is making a landmark push into cancer diagnostics with its agreement to acquire Exact Sciences for roughly $23 billion, including $21
patrickwareing.com
November 21, 2025 at 11:45 AM
patrickwareing.bsky.social
Precise Bio Achieves World’s First 3D-Printed Human Cornea Transplant, Advancing Regenerative Medicine

patrickwareing.com/news/precise...
Precise Bio Achieves World’s First 3D-Printed Human Cornea Transplant, Advancing Regenerative Medicine - Patrick Wareing
Precise Bio, a clinical-stage regenerative medicine company specializing in 3D bioprinted tissues, announced the successful implantation of PB-001, the
patrickwareing.com
November 20, 2025 at 4:30 PM
patrickwareing.bsky.social
Celltrion Secures $350 Million Antibody Deal Option, Expanding Beyond Biosimilars into Novel Antibody Development

patrickwareing.com/news/celltri...
Celltrion Secures $350 Million Antibody Deal Option, Expanding Beyond Biosimilars into Novel Antibody Development - Patrick Wareing
South Korean biopharmaceutical giant Celltrion announced a major strategic deal with Korea-based TriOar Therapeutics, acquiring an option to license the
patrickwareing.com
November 20, 2025 at 2:30 PM
patrickwareing.bsky.social
Tempest Therapeutics Completes All-Stock Acquisition of Factor’s CAR-T Pipeline and CEO in Strategic Move

patrickwareing.com/news/tempest...
Tempest Therapeutics Completes All-Stock Acquisition of Factor’s CAR-T Pipeline and CEO in Strategic Move - Patrick Wareing
After a period of significant restructuring marked by layoffs, Tempest Therapeutics has turned to Factor Bioscience for a lifeline by acquiring several
patrickwareing.com
November 20, 2025 at 11:45 AM
patrickwareing.bsky.social
Solve Therapeutics Raises $120 Million to Advance Next-Gen Antibody-Drug Conjugates in Solid Tumor Trials

patrickwareing.com/news/solve-t...
Solve Therapeutics Raises $120 Million to Advance Next-Gen Antibody-Drug Conjugates in Solid Tumor Trials - Patrick Wareing
Solve Therapeutics, a San Diego-based clinical-stage biotech, announced it has raised $120 million in a heavily oversubscribed financing to push its pipeline
patrickwareing.com
November 19, 2025 at 3:30 PM
patrickwareing.bsky.social
Sofinnova Partners Closes €650 Million Fund to Propel Early-Stage Biotech and Medtech Innovation

patrickwareing.com/news/sofinno...
Sofinnova Partners Closes €650 Million Fund to Propel Early-Stage Biotech and Medtech Innovation - Patrick Wareing
Sofinnova Partners, a leading European life sciences venture capital firm with offices in Paris, London, and Milan, announced the successful close of its
patrickwareing.com
November 19, 2025 at 2:00 PM
patrickwareing.bsky.social
Sensei Biotherapeutics Halts Research, Implements Major Layoffs and Strategic Review

patrickwareing.com/news/sensei-...
Sensei Biotherapeutics Halts Research, Implements Major Layoffs and Strategic Review - Patrick Wareing
Sensei Biotherapeutics , a clinical-stage biotechnology firm focused on next-generation cancer therapeutics, announced a cessation of all research and
patrickwareing.com
November 19, 2025 at 11:45 AM
patrickwareing.bsky.social
Korro Therapeutics Cuts Workforce by 34% After RNA Editing Drug Disappoints in Key Genetic Disease Trial

patrickwareing.com/news/korro-t...
Korro Therapeutics Cuts Workforce by 34% After RNA Editing Drug Disappoints in Key Genetic Disease Trial - Patrick Wareing
Korro Therapeutics announced a major retrenchment after disappointing results in a closely watched Phase I/IIa clinical trial forced the company to abandon
patrickwareing.com
November 18, 2025 at 4:15 PM